Robert T Nolte

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10888356/publications.pdf

Version: 2024-02-01

15	4,361	567281 15	996975 15
papers	citations	h-index	g-index

15	15	15	4894
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-Î³. Nature, 1998, 395, 137-143.	27.8	1,818
2	Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARÎ±. Nature, 2002, 415, 813-817.	27.8	598
3	Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity. Science, 2000, 288, 1822-1825.	12.6	342
4	Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature, 1998, 395, 199-202.	27.8	325
5	Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor. Journal of Medicinal Chemistry, 2008, 51, 4632-4640.	6.4	319
6	Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors. Journal of Medicinal Chemistry, 2007, 50, 4453-4470.	6.4	182
7	Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2203-2207.	2.2	144
8	Discovery and Evaluation of 2-Anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 1610-1619.	6.4	120
9	X-ray Crystal Structures of the Estrogen-related Receptor-Î³ Ligand Binding Domain in Three Functional States Reveal the Molecular Basis of Small Molecule Regulation. Journal of Biological Chemistry, 2006, 281, 37773-37781.	3.4	120
10	Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Medicinal Chemistry Letters, 2013, 4, 1238-1243.	2.8	117
11	Crystal Structures of the Catalytic Domain of Phosphodiesterase 4B Complexed with AMP, 8-Br-AMP, and Rolipram. Journal of Molecular Biology, 2004, 337, 355-365.	4.2	113
12	Structure of Rev-erbÎ± bound to N-CoR reveals a unique mechanism of nuclear receptorâ€“co-repressor interaction. Nature Structural and Molecular Biology, 2010, 17, 808-814.	8.2	80
13	Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1773-1778.	2.2	36
14	Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3519-3523.	2.2	27
15	Co-crystal structure guided array synthesis of PPARÎ³ inverse agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3916-3920.	2.2	20